Theratome Bio Inc
Theratome Bio develops AI-enhanced, cell-free regenerative biologics to preserve tissues and treat ocular and ischemic injuries. The company produces second-generation secretomes—secreted factors from adult stem cells—optimized by stimulation protocols and refined to remove undesired components, delivering off-the-shelf therapeutics with freezer-temperature storage and immediate bioavailability. Their platform combines artificial intelligence for biomarker targeting with biologics technologies such as secretomes, exosomes, micro-RNAs, and metabolites to tune anti-inflammatory and organ-preserving activity. Lead programs include a product to extend transplant organ shelf life and therapies for dry eye, ischemic brain injury, concussion, and acute kidney injury. Theratome is a development-stage therapeutics company targeting partnerships with biotechnology and pharmaceutical organizations.
Theratome Bio Inc
Theratome Bio develops AI-enhanced, cell-free regenerative biologics to preserve tissues and treat ocular and ischemic injuries. The company produces second-generation secretomes—secreted factors from adult stem cells—optimized by stimulation protocols and refined to remove undesired components, delivering off-the-shelf therapeutics with freezer-temperature storage and immediate bioavailability. Their platform combines artificial intelligence for biomarker targeting with biologics technologies such as secretomes, exosomes, micro-RNAs, and metabolites to tune anti-inflammatory and organ-preserving activity. Lead programs include a product to extend transplant organ shelf life and therapies for dry eye, ischemic brain injury, concussion, and acute kidney injury. Theratome is a development-stage therapeutics company targeting partnerships with biotechnology and pharmaceutical organizations.
TL;DR
Stage: Development-stage therapeutics company
Platform: AI-enhanced, cell-free secretome biologics
Lead programs: Organ transplant preservation (Thera-103) and dry eye disease (Thera-102)
Recent milestones: Completed manufacturing technology transfer (Jun 24, 2024); commenced dry eye study in dogs (Aug 1, 2024)
Funding signal: Series A (Oct 17, 2018) — Texas HALO Fund; amount undisclosed